{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:11:46Z","timestamp":1761948706237,"version":"3.41.0"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 23-year-old man with metastatic osteosarcoma, with disease progression on conventional chemotherapy, was treated with regorafenib, a multikinase inhibitor. After treatment for 6 months with regorafenib, <jats:sup>18<\/jats:sup>F-FDG PET\/CT scan demonstrated FDG uptake in a necrotic space-occupying lesion involving tail of pancreas. After imaging, patient described symptoms of epigastric pain with elevated serum amylase and lipase levels, confirming diagnosis of regorafenib-induced pancreatitis, because patient had no other causative factors of pancreatitis. Physicians should be aware of rare and possibly clinically silent adverse effects of tyrosine kinase inhibitors, like acute pancreatitis, and recognize the <jats:sup>18<\/jats:sup>F-FDG PET\/CT findings to guide appropriate clinical management.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003449","type":"journal-article","created":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T10:14:03Z","timestamp":1607940843000},"page":"e256-e257","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Regorafenib-Associated Acute Pancreatitis Diagnosed on 18F-FDG PET\/CT"],"prefix":"10.1097","volume":"46","author":[{"given":"Melvika","family":"Pereira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ameya D.","family":"Puranik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilendu","family":"Purandare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sneha","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archi","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkatesh","family":"Rangarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-3-319-91442-8_3","article-title":"Regorafenib","volume":"211","year":"2018","journal-title":"Recent Results Cancer Res"},{"key":"bib2-20250621","first-page":"1469","article-title":"Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors","volume":"9","year":"2003","journal-title":"Clin Cancer Res"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1200\/JCO.18.02374","article-title":"Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","article-title":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study","volume":"20","year":"2019","journal-title":"Lancet Oncol"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jons.2016.07.002","article-title":"Case report of a renal cell carcinoma patient with acute pancreatitis under both sunitinib and axitinib treatment","volume":"2","year":"2016","journal-title":"J Oncol Sci"},{"key":"bib6-20250621","first-page":"115","article-title":"Sunitinib-associated acute pancreatitis: a case report","volume":"1","year":"2017","journal-title":"EJMO"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1097\/RLU.0000000000002692","article-title":"Focal immunotherapy-induced pancreatitis mimicking metastasis on FDG PET\/CT","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1097\/RLU.0000000000000940","article-title":"Pancreatitis secondary to anti-programmed death receptor 1 immunotherapy diagnosed by FDG PET\/CT","volume":"40","year":"2015","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T21:03:33Z","timestamp":1750539813000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003449","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}